BACKGROUND: This research was conducted is to assess the effect of booster doses of the trivalent influenza vaccine in adult inflammatory bowel disease (IBD) patients treated with anti-tumor necrosis factor (TNF)-α agents and/or immunomodulators. METHODS:Adult IBD patients and healthy individuals were subcutaneously administered the trivalent influenza vaccine. They were randomized into two groups: the single vaccination group and the two vaccination booster group. Blood samples were collected, and the antibody titers against each influenza strain were determined by hemagglutination inhibition at 3 different time points (pre-vaccination, 3 weeks post-vaccination, and after the flu season) in the single vaccination group and at 4 time points (pre-vaccination, 3 weeks post-first vaccination, 3 weeks post-second vaccination, and after the flu season) in the booster vaccination group. RESULTS:Seventy-eight IBD patients and 11 healthy controls were randomized into the single vaccination group and the booster vaccination group. Twenty-nine patients received immunomodulators; 21 receivedanti-TNF-α agents; and 28 received a combination of both. No significant differences were observed in the evaluated immune response parameters between 3 weeks post-vaccination in the single vaccination group and 3 weeks post-second vaccination in the booster vaccination group (geometric mean titers: H1N1, p = 0.09; H3N2: p = 0.99; B: p = 0.94). A higher pre-vaccination titer was significantly associated with sufficient seroprotection rate after vaccination for the H1N1 strain (odds ratio 11.93, p = 0.03). CONCLUSIONS: The second booster of trivalent influenza vaccination did not improve the immune response in adult IBD patients who were treated with immunomodulators and/or anti-TNF-α agents.
RCT Entities:
BACKGROUND: This research was conducted is to assess the effect of booster doses of the trivalent influenza vaccine in adult inflammatory bowel disease (IBD) patients treated with anti-tumornecrosis factor (TNF)-α agents and/or immunomodulators. METHODS: Adult IBD patients and healthy individuals were subcutaneously administered the trivalent influenza vaccine. They were randomized into two groups: the single vaccination group and the two vaccination booster group. Blood samples were collected, and the antibody titers against each influenza strain were determined by hemagglutination inhibition at 3 different time points (pre-vaccination, 3 weeks post-vaccination, and after the flu season) in the single vaccination group and at 4 time points (pre-vaccination, 3 weeks post-first vaccination, 3 weeks post-second vaccination, and after the flu season) in the booster vaccination group. RESULTS: Seventy-eight IBD patients and 11 healthy controls were randomized into the single vaccination group and the booster vaccination group. Twenty-nine patients received immunomodulators; 21 received anti-TNF-α agents; and 28 received a combination of both. No significant differences were observed in the evaluated immune response parameters between 3 weeks post-vaccination in the single vaccination group and 3 weeks post-second vaccination in the booster vaccination group (geometric mean titers: H1N1, p = 0.09; H3N2: p = 0.99; B: p = 0.94). A higher pre-vaccination titer was significantly associated with sufficient seroprotection rate after vaccination for the H1N1 strain (odds ratio 11.93, p = 0.03). CONCLUSIONS: The second booster of trivalent influenza vaccination did not improve the immune response in adult IBD patients who were treated with immunomodulators and/or anti-TNF-α agents.
Authors: Jean-François Rahier; Pavol Papay; Julia Salleron; Shaji Sebastian; Manuela Marzo; Laurent Peyrin-Biroulet; Valle Garcia-Sanchez; Walter Fries; Dirk P van Asseldonk; Klaudia Farkas; Nanne K de Boer; Taina Sipponen; Pierre Ellul; Edouard Louis; Simon T C Peake; Uri Kopylov; Jochen Maul; Badira Makhoul; Gionata Fiorino; Yazdan Yazdanpanah; Maria Chaparro Journal: Gut Date: 2011-01-26 Impact factor: 23.059
Authors: Kathleen M Neuzil; Lisa A Jackson; Jennifer Nelson; Alexander Klimov; Nancy Cox; Carolyn B Bridges; John Dunn; Frank DeStefano; David Shay Journal: J Infect Dis Date: 2006-09-11 Impact factor: 5.226
Authors: G Andrisani; D Frasca; M Romero; A Armuzzi; C Felice; M Marzo; D Pugliese; A Papa; G Mocci; I De Vitis; G L Rapaccini; B B Blomberg; L Guidi Journal: J Crohns Colitis Date: 2012-06-05 Impact factor: 9.071
Authors: William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda Journal: JAMA Date: 2004-09-15 Impact factor: 56.272
Authors: Sandra Maria Barbalho; Julia Novaes Matias; Uri Adrian Prync Flato; Joao Paulo Galletti Pilon; Piero Bitelli; Marcos Alberto Pagani Junior; Antonelly Cassio Alves de Carvalho; Jesselina Francisco Dos Santos Haber; Carlos Henrique Bertoni Reis; Ricardo de Alvares Goulart Journal: Gastroenterology Res Date: 2021-02-19
Authors: Jennifer L Jones; Frances Tse; Matthew W Carroll; Jennifer C deBruyn; Shelly A McNeil; Anne Pham-Huy; Cynthia H Seow; Lisa L Barrett; Talat Bessissow; Nicholas Carman; Gil Y Melmed; Otto G Vanderkooi; John K Marshall; Eric I Benchimol Journal: J Can Assoc Gastroenterol Date: 2021-07-29
Authors: Ralley E Prentice; Clarissa Rentsch; Aysha H Al-Ani; Eva Zhang; Douglas Johnson; John Halliday; Robert Bryant; Jacob Begun; Mark G Ward; Peter J Lewindon; Susan J Connor; Simon Ghaly; Britt Christensen Journal: GastroHep Date: 2021-07-23